share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K：重大事件
美股sec公告 ·  04/26 16:45
Moomoo AI 已提取核心信息
On April 25, 2024, Avenue Therapeutics, Inc., a specialty pharmaceutical company, filed an amendment to its certificate of incorporation to effectuate a 1-for-75 reverse stock split of its common stock. This action was approved by the company's stockholders following a definitive information statement filed with the SEC on March 18, 2024. The board of directors had previously determined the reverse stock split ratio on April 10, 2024. The reverse stock split, which was implemented to comply with Nasdaq's minimum bid price requirement, reduced the number of outstanding shares from approximately 44.7 million to about 0.6 million, adjusting for fractional shares. The split became effective on April 26, 2024, with the common stock trading on a post-split basis from the opening of business on that date. The company's common stock retained its ticker symbol 'ATXI' and was assigned a new CUSIP number. Avenue Therapeutics also announced the reverse stock split in a press release on April 24, 2024.
On April 25, 2024, Avenue Therapeutics, Inc., a specialty pharmaceutical company, filed an amendment to its certificate of incorporation to effectuate a 1-for-75 reverse stock split of its common stock. This action was approved by the company's stockholders following a definitive information statement filed with the SEC on March 18, 2024. The board of directors had previously determined the reverse stock split ratio on April 10, 2024. The reverse stock split, which was implemented to comply with Nasdaq's minimum bid price requirement, reduced the number of outstanding shares from approximately 44.7 million to about 0.6 million, adjusting for fractional shares. The split became effective on April 26, 2024, with the common stock trading on a post-split basis from the opening of business on that date. The company's common stock retained its ticker symbol 'ATXI' and was assigned a new CUSIP number. Avenue Therapeutics also announced the reverse stock split in a press release on April 24, 2024.
2024年4月25日，专业制药公司Avenue Therapeutics, Inc. 提交了公司注册证书修正案，以1比75的比例对其普通股进行反向分割。在2024年3月18日向美国证券交易委员会提交最终信息声明后，该行动获得了公司股东的批准。董事会此前已在 2024 年 4 月 10 日确定了反向股票拆分比率。反向股票拆分是为了遵守纳斯达克的最低出价要求而实施的，经零星股票调整后，已发行股票的数量从约4,470万股减少到约60万股。拆分于2024年4月26日生效，普通股自该日开业之日起在拆分后的基础上交易。该公司的普通股保留了其股票代码 “ATXI”，并被分配了新的CUSIP编号。Avenue Therapeutics还在2024年4月24日的新闻稿中宣布了反向股票拆分。
2024年4月25日，专业制药公司Avenue Therapeutics, Inc. 提交了公司注册证书修正案，以1比75的比例对其普通股进行反向分割。在2024年3月18日向美国证券交易委员会提交最终信息声明后，该行动获得了公司股东的批准。董事会此前已在 2024 年 4 月 10 日确定了反向股票拆分比率。反向股票拆分是为了遵守纳斯达克的最低出价要求而实施的，经零星股票调整后，已发行股票的数量从约4,470万股减少到约60万股。拆分于2024年4月26日生效，普通股自该日开业之日起在拆分后的基础上交易。该公司的普通股保留了其股票代码 “ATXI”，并被分配了新的CUSIP编号。Avenue Therapeutics还在2024年4月24日的新闻稿中宣布了反向股票拆分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息